Population Pharmacokinetics of Dexmedetomidine in ICU Patients
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Dexmedetomidine is a new, highly selective and potent alpha2-adrenoreceptor agonist
registered for sedation of patients in intensive care units. Although the pharmacokinetics of
dexmedetomidine have been studied previously also in an ICU setting, there is no information
on the pharmacokinetics of long-lasting (>48 hours) dexmedetomidine infusions in humans.
The aim of this study is to study the pharmacokinetics of long-lasting dexmedetomidine
infusions in ICU patients using the population pharmacokinetics approach.